Results 181 to 190 of about 731,872 (346)

THU0197 Effects of tocilizumab, an anti-interleukin-6 receptor antibody, on serum lipid and adipokine levels in patients with rheumatoid arthritis [PDF]

, 2018
E. C. Hoffman, Michal A. Rahat, Joy Feld, Muna Elias, Itzhak Rosner, Lisa Kaly, I. Lavi, Devy Zisman   +7 more
openalex   +1 more source

Natural Products Inspired Scaffold Diversification Leads to Unnatural Molecular Warhead and Covalent Strategy to Modulating Protein Function through Electrophilic Bromine Transfer

Advanced Science, EarlyView.
We report a new thiolate‐reactive α,α‐gem‐dibromo lactam warhead that activates transcription factor Nrf2 and demonstrates anti‐inflammatory activities, which have implications in cancer, neurodegeneration, and cardiovascular diseases. RNA‐seq illuminated detailed transcriptional profiles, and chemical reactions with cysteine‐containing compounds ...
Beau R. Brummel, Sofia Kokkaliari, Qiwen Gao, Jinjing Chen, Larissa Costa de Almeida, Srinivasarao Tenneti, Derek A. Leas, Eli Levit, Lewis S. Alexander, Khalil A. Abboud, Pingrong Wei, Michael D. Cameron, James R. Rocca, Ranjala Ratnayake, Donna D. Zhang, Hendrik Luesch, Robert W. Huigens III   +16 more
wiley   +1 more source

Benefit and risk associated with interleukin-6 receptor inhibitor administration during severe COVID-19: a retrospective multicentric study. [PDF]

Sci Rep
Lefèvre C, Funck-Brentano T, Cachanado M, Plocque A, Youinou M, Fels A, Pène F, Savale L, Montani D, Voisin O, Bintein F, Wildenberg L, Philippe A, Legriel S, Roche N, Burgel PR, Tran M, Noël N, Baillard C, Duranteau J, Chatellier G, Philippart F.   +21 more
europepmc   +1 more source

Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab. [PDF]

Open Heart, 2023
Woxholt S, Ueland T, Aukrust P, Anstensrud AK, Broch K, Tøllefsen IM, Ryan L, Bendz B, Hopp E, Kløw NE, Seljeflot I, Halvorsen B, Dahl TB, Huse C, Andersen GØ, Gullestad L, Wiseth R, Amundsen BH, Damas JK, Kleveland O.   +19 more
europepmc   +1 more source

Discovery of H2 Receptor Antagonists as Colistin Enhancers by Targeting Acid Stress Response

Advanced Science, EarlyView.
This study identifies YqgB as a key target for restoring colistin susceptibility in mcr‐positive pathogens under acidic conditions by remodeling phospholipid composition and reducing LPS modification. Deep learning‐based screening reveals H2 receptor antagonists as novel colistin adjuvants. Further investigations indicate that ranitidine and famotidine
Jinju Cai, Mengping He, Jianya Luo, Shuang Zhou, Tengyue Zhang, Jianing Li, Zhiqiang Wang, Yuan Liu   +7 more
wiley   +1 more source

The association between cerebrospinal fluid interleukin-6, soluble interleukin-6 receptor, and interleukin-6 trans-signalling binary complex with postoperative delirium: an observational cohort study. [PDF]

BJA Open
Wu JG, Taylor J, Kunkel D, Maze M, Pearce RA, Sanders RD, Lennertz R.   +6 more
europepmc   +1 more source

Improved Systemic Immunochemotherapy Employing an Oxaliplatin‐TLR7/8 Agonist Prodrug Strategy

Advanced Science, EarlyView.
A platinum(IV) prodrug is developed to systemically deliver the TLR7/8 agonist gardiquimod. Tumor‐targeting is mediated by an albumin‐binding maleimide, which limits premature complex activation. Ox‐Gardi‐Mal accumulates specifically in the tumor, where it activates the immune system.
Michael Gutmann, Martijn Dijkstra, Philipp Salomon, Jamie Cowles, Anja Federa, Dina Baier, Carola Jaunecker, Iemima Semerean, Venla Karvonen, Christine Pirker, Maria Sibilia, Dietmar Herndler‐Brandstetter, Petra Heffeter, Bernhard K. Keppler, Christian R. Kowol, Walter Berger   +15 more
wiley   +1 more source

The effects of interleukin-6-receptor inhibition on monocytes in STEMI: a substudy of the ASSAIL-MI trial. [PDF]

EBioMedicine
Huse C, Murphy SL, Yang K, Balzer NR, Stokke MK, Anstensrud AK, Bjerkeli V, Rentz T, Jha PK, Ugland HK, Michelsen AE, Ueland T, Holm S, Tøllefsen IM, Bendz B, Kleveland O, Andersen GØ, Gullestad L, Louch WE, Woxholt S, Osnes L, Broch K, Ulas T, Aukrust P, Libby P, Halvorsen B, Dahl TB.   +26 more
europepmc   +1 more source

Therapeutic potential of single-nucleotide polymorphism-mediated interleukin-6 receptor blockade in cancer treatment: A Mendelian randomization study. [PDF]

Heliyon, 2023
Zhang S, Zhang W, Sun H, Xue R, Lv Q.
europepmc   +1 more source

Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b

, 2009
Katia Todoerti, Valentina Barbui, Olga Pedrini, Marta Lionetti, Gianluca Fossati, Paolo Mascagni, Alessandro Rambaldi, Antonino Neri, Martino Introna, L. Tallone Lombardi, Josée Golay   +10 more
openalex   +2 more sources